Preclinical data presented today during the virtual meeting II of the American Association for Cancer Research (AACR), being held June 22 – 24, 2020, shows that an investigational drug called TXR-311 demonstrated significant efficacy and good tolerability in in vivo studies for the potential treatment of hepatocellular carcinoma (HCC).